

Research Article

# Incidence and Predictors of Ocular Hypertension After Intravitreal Injection of Bevacizumab Among Patients Attending KCMC Hospital, 2023–2024

John Ambakisye<sup>1,2,3</sup>, Furahin Godfrey Mndeme<sup>1,2</sup>, William Makupa<sup>1,2</sup>

1. Kilimanjaro Christian Medical University, Tanzania; 2. Ophthalmology Department, Kilimanjaro Christian Medical Centre, Tanzania; 3. Njombe Regional Referral Hospital, Tanzania

**Objective:** This study aimed to evaluate the incidence, patterns, and determinants of ocular hypertension (OH) following Bevacizumab Intravitreal injections for various retinal diseases at KCMC Hospital, Tanzania.

**Methods:** A prospective cohort study was conducted from August 2023 to July 2024, involving 120 participants. OH was defined as an intraocular pressure (IOP) >21 mmHg or an increase >5 mmHg from baseline. Data on demographics, injection frequency, ocular conditions, and systemic factors were collected. IOP was measured at baseline, immediately post-injection, and at six-week intervals during follow-up. Paired t-tests compared mean IOP differences, and Poisson regression identified associated factors.

**Results:** Participants' median age was 62 years, diabetic macular edema (52.5%) being the most common indication. OH incidence was 15%, significantly associated with the number of injections (adjusted hazard ratio [AHR] 2.17, 95% CI 1.56–3.16,  $p < 0.001$ ) and history of YAG laser capsulotomy (AHR 0.33, 95% CI 0.12–0.88,  $p = 0.028$ ). Temporary post-injection IOP spikes normalized within 60 minutes.

**Conclusion:** The study revealed a higher incidence of ocular hypertension following Bevacizumab injections compared to other studies. Significant factors included injection frequency and a history of YAG laser capsulotomy, with repeated injections leading to delayed normalization of short term intraocular pressure and increased short term (within an hour) IOP spikes during subsequent visits.

## Introduction

In recent years anti-VEGF agents such as Bevacizumab (Avastin) have revolutionized the management of various retinal diseases worldwide, including diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusions. Bevacizumab, a recombinant humanized monoclonal IgG1 inhibits VEGF-A which lead to suppression of pathological angiogenesis and vascular leakage, thereby preserving visual function<sup>[1]</sup>

While the therapeutic benefits of Bevacizumab are well-documented, Intravitreal anti-VEGF injections are associated with potential complications, notably ocular hypertension (OHT), which can lead to glaucomatous damage if left unmanaged<sup>[2]</sup>. OHT refers to a condition where the intraocular pressure (IOP) is elevated above the normal range (typically >21 mmHg) without any detectable optic nerve damage and visual field loss.

The exact mechanisms by which Bevacizumab causes OHT are not entirely understood, but several theories exist. VEGF inhibition might affect the regulation of aqueous humor dynamics, potentially leading to increased production or decreased outflow. Intravitreal injections can induce an inflammatory response, causing trabecular meshwork dysfunction, leading to reduced outflow and increased IOP. The injected fluid itself could cause a transient increase in IOP. Additionally, VEGF plays a role in maintaining normal ocular blood flow; its inhibition might disrupt this balance, or the TM being mechanically blocked by protein clumps or foreign particles<sup>[3]</sup>.

The global burden of ocular hypertension following Intravitreal Bevacizumab injections varies significantly across regions. Studies have shown that the incidence ranges from 4% to 15%, depending on patient demographics, underlying conditions, and the number of injections received<sup>[3]</sup>

Previous studies have explored risk factors influencing OHT, such as the number of injections pre-existing glaucoma and history of YAG capsulotomy with mixed and inconclusive results<sup>[4][5][6][7]</sup>.

Transient intraocular pressure (IOP) spikes immediately following Bevacizumab Intravitreal injections have been reported in several studies; however, the incidence of these spikes varies significantly across different research investigations<sup>[8][9][10]</sup>.

In Africa, comprehensive data is scarce; however, available studies suggest that the prevalence might be comparable to global trends. Sub-Saharan Africa and East Africa face additional challenges, such as

limited access to advanced ophthalmic care and follow-up, which could affect the management and outcomes of patients receiving Intravitreal injections. In Tanzania, specific data on the prevalence, pattern and factor associated with ocular hypertension post-Bevacizumab injection is limited, highlighting a significant gap in regional research. This study aim to evaluate the incidence and predictor of ocular hypertension at KCMC hospital in northern part of Tanzania, this will help identify high-risk patients receiving Intravitreal Bevacizumab injections and guide clinicians in monitoring IOP changes potentially reducing the burden of glaucoma improving the quality of life for patients receiving Intravitreal Bevacizumab injections.

## Materials and Methods

A prospective cohort study was conducted at the Ophthalmology Department of Kilimanjaro Christian Medical Centre (KCMC), a zonal referral hospital in Moshi Municipal, Kilimanjaro Region, Tanzania, from August 2023 to July 2024. The study was approved by the Kilimanjaro Christian Medical University College Research and Ethical Committee (Ref PG.83/2023), and all participants provided written informed consent before enrollment. The study adhered to the tenets of the declaration of Helsinki. Adult patients scheduled to receive Intravitreal Bevacizumab injections (Avastin; Genentech Inc., San Francisco, CA, USA) were recruited from the outpatient eye clinic at KCMC Hospital. Data collected included demographic information, ocular diagnosis, and indications for injection, intraocular pressure at each visit, lens status, systemic hypertension, history of YAG laser capsulotomy within six months, history of retinal surgery and number of injections.

Exclusion criteria were Glaucoma patient, Glaucoma suspect (IOP > 21 mmHg, and/or cup-to-disc ratio > 0.5), History of other Intravitreal drug injections in the same eye within 6 months (steroid, gancyclovir patient with Any pathology in either exposed or non-exposed eye that may lead to OH or secondary glaucoma and make interpretation difficult include uveitis, pseudoexfoliation syndrome, pigmentary dispersion syndrome, iridocorneal endothelial syndrome).

A consecutive sampling technique was used where by all patients were considered for the study until sample size was reached.

Both eye from each patient was included in the study. The injected eye was designated as the exposed eye, while the non-injected fellow eye served as the comparison (non-exposed eye). Baseline intraocular pressure (IOP) was measured before administering the Intravitreal Bevacizumab (BVM) injection using

an Icare tonometer (IC100). All measurements and injection were conducted by the principal researcher, a senior ophthalmology resident in his fourth year.

Intravitreal injections were performed in a minor operating theater under aseptic conditions. The procedure involved the application of 0.5% amethocaine as topical anesthesia, followed by irrigation of the conjunctiva fornices with 5% Povidone-iodine. The lid margin and periorbital skin were disinfected using 10% Povidone-iodine. After a gentle 30-second massage, sterile skin drapes and a lid speculum were applied to prepare the site for injection. Then Intravitreal BVM injection was prepared by drawing up approximately 0.1 ml of 2.5mg BVM into 1ml insulin syringe then was injected through the inferior temporal or superior temporal pars plana region at 3.5 mm from the limbus in pseudophakic and 4 mm from the limbus, in a phakic patient, Firm pressure was applied to the injection site with a sterile cotton-tip applicator for at least 20second immediately on retrieval of the injection needle to minimize vitreous reflux.. The patient was discharged with topical dexamethasone-chloramphenicol twice a day for seven days. The IOP was measured before and immediately after injection at 5 minutes, 15 minutes, 30 minutes, and 60minutes then measured at follow-up visits of 6-week intervals for 6 months.

At 6-weekfollow-up visit, the IOP measurement was obtained before the second

Injection to avoid the confounding effect from the short-term IOP rising. The mean IOP at each visit was obtained from the average of three measurements. The last IOP was measured after 6week of last injection to measure the effect of that injection.

The primary outcome measure was the proportion of eyes developing persistence IOP elevation defined as either an IOP > 21 mmHg or an increase of more than 5mmhg from the baseline.

The criteria is chosen based on a previously published definition<sup>[11][12]</sup>

Data was analyzed using STATA (Stata Corp LLC, College Station, Texas, USA) version 17). Chi-square ( $\chi^2$ ) was used to determine the difference in proportion of IOP by participants' characteristics while paired sample Student's *t* tests was used to determine any significant difference in pre-injection and post-injection IOP at p-value of <0.05 of the study participants. The log-rank test was used to confirm the significance difference of the ocular hypertension in the number of injections. Poisson distribution regression model was used to assess the factors associated with the ocular hypertension. Multivariate regression analysis of statistically significant potential predictors was performed by obtain the adjusted hazard ratio (AHR) to identify independent predictors of IOP changes. Variables with a P-value of < 0.05 were considered statistically associated with the event.

## Results

The median age of study participants was 62 years. The majority of participants were male (59%), and 58% had received more than three injections. A total of 16.7% of eyes had undergone YAG laser capsulotomy (Table 1). Diabetic macular edema (52.5%) was the leading indication for Bevacizumab injections, followed by vitreous hemorrhage (22.5%) (Figure1).

Variable	Frequency	Percentage
<b>Sex of the participant</b>		
Male	71	59.2
Female	49	40.8
<b>Age of the participant</b>		
≤70	96	82.5
>70	21	17.5
<i>Median(IQR)</i>	62(54.5-69)	
<b>Lens status</b>		
phakic	95	79.2
pseudophakic	25	20.8
<b>Number of injections</b>		
Less than three injections	50	41.7
Three injections or more	70	58.3
<b>YAG laser capsulotomy</b>		
Yes	20	16.7
No	100	83.3
<b>History of retina surgery</b>		
No	106	88.3
Yes	14	11.7
<b>History of hypertension</b>		
Yes	79	65.8
No	41	34.2
<b>RVO</b>		
No	107	89.2
Yes	13	10.8

Variable	Frequency	Percentage
CNV		
No	111	92.5
Yes	9	7.5
VH		
No	93	77.5
Yes	27	22.5
DME		
Yes	57	47
No	63	52

Table 1. Participants' background characteristics (N=120).





Figure 1. Bevacizumab indication among participants (N=120).


The overall incidence of ocular hypertension was 15% (18/120). Where 9.2% (11/120) of study eyes were found to have persistence ocular hypertension using criteria of any increase in intraocular pressure (IOP > 21 mmHg), and 5.8 % (7/120) were identified with persistent ocular hypertension using criteria of an increase in IOP of more than 5 mmHg from baseline. Among the eyes, 1.7% (2 out of 120) showed persistent IOP elevations exceeding 30 mmHg.

Short-term intraocular pressure (IOP) spikes were observed in injected eyes following Bevacizumab administration, with distinct patterns between the first and third injections. In the first injection, 95% of eyes experienced IOP spikes, with 5% exceeding 50 mmHg at five minutes. Baseline IOP was  $14 \pm 2.86$  mmHg, rising to  $34.6 \pm 5.74$  mmHg five minutes post-injection, and normalizing to  $14.6 \pm 2.52$  mmHg within 60 minutes. Most eyes (98%) returned to IOP below 21 mmHg within 30 minutes, and the rest within 60 minutes. In the third injection, 97% of eyes had IOP spikes, with 21% exceeding 50 mmHg. Baseline IOP was slightly higher at  $15.8 \pm 4.15$  mmHg, peaking at  $50 \pm 16.86$  mmHg and stabilizing at  $17.1 \pm 4.04$  mmHg within 60 minutes. Normalization was slower, with 72% returning to below 21 mmHg within 30 minutes, and 28% requiring up to 60 minutes. Non-injected eyes showed minimal effects, with transient IOP increases in 3% during the first injection and 4% during the third (Figure 2 and Figure 3).



**Figure 2.** Short term pattern IOP spike after Bevacizumab injection among the study participant for first injection (Visit) (N= 120)





**Figure 3.** Short term pattern IOP spike after Bevacizumab injection among the study participants at third injection (12wk) (N= 120)

The mean intraocular pressure (IOP) in the injected eye progressively increased with the number of Bevacizumab injections, while the IOP in the non-injected eye remained stable throughout the study period. Before the first injection, the mean IOP was  $14 \pm 2.86$  mmHg. After each subsequent injection, the mean IOPs at the second (6 weeks), third (12 weeks), fourth (18 weeks), and final follow-up visits were  $14.7 \pm 3.06$  mmHg,  $15.8 \pm 3.56$  mmHg,  $16.2 \pm 3.89$  mmHg, and  $16.4 \pm 4.21$  mmHg, respectively. These increases in IOP were statistically significant at each follow-up visit in the injected eye, indicating a progressive rise in pressure over time. In contrast, the non-injected eye showed no significant change in IOP during the study period (Table 2).

Variable	Injected eye		P-value	Non injected eye		P-value
	Mean(95%CI)	SD		Mean(95%CI)	SD	
Baseline IOP	14(13.5-14.5)	±2.86		14.4(13.8-14.9)	±3.01	
IOP 2 <sup>nd</sup> visit(6wk)	14.7(14.1-15.2)	±3.06	0.0137	14.4(13.8-14.9)	±2.89	0.9728
IOP 3 <sup>rd</sup> visit(12wk)	15.8(15.2-16.4)	±3.56	<0.001	14.7(14.1-15.2)	±2.82	0.2323
IOP 4th visit(18wk)	16.2(15.5-16.9)	±3.89	<0.001	14.6(14.1-14.9)	±2.45	0.4538
Last visit IOP(24wk)	16.4(15.7-17.2)	±4.21	<0.001	14.7(14.2-15.1)	±2.43	0.2072

**Table 2.** Mean Intraocular pressure at baseline and second, third, fourth, and last visit after Intravitreal injection of Bevacizumab in injected and control eye.

Ocular hypertension significantly differed by number of injection ( $\chi^2=11.3613$ , P-value=0.001) and YAG laser capsulotomy ( $\chi^2=7.5294$ , P-value=0.006) (**Table 3**).

In adjusted analysis, number of injection and history of YAG laser capsulotomy were factors that significantly associated with ocular hypertension. For every increase in number of injections, the risk of having ocular hypertension increase is 2.2 times significant higher (CHR=2.17; 95%CI (1.56-3.16) P-value< 0.001) after adjusting for YAG, while compared to participants who had YAG those without YAG, had 67% significant lower risk of having ocular hypertension (AHR=0.33; 95%CI (0.12-0.88) P-value= 0.028) after adjusting for number of number of injections age and sex (**Table 4**).

Variable	Ocular Hypertension		$\chi^2$	P-value
	No	Yes		
	n (%)	n (%)		
<b>Sex</b>			1.8998	0.168
Male	63(88.7)	8(11.3)		
Female	39(79.6)	10(20.4)		
<b>Age of the participant</b>			0.3271	0.567
≤70	85(85.9)	14(14.1)		
>70	17(81.0)	4(19.0)		
<b>Lens status</b>			0.6192	0.431
Phakic	82(86.3)	13(13.7)		
pseudophakic	20(80)	5(20)		
<b>Number of injections</b>			11.3613	0.001
Less than three injections	49(98)	1(2)		
Three injection or more	53(75.7)	17(24.3)		
<b>YAG laser capsulotomy.</b>			7.5294	0.006
Yes	13(65.0)	7(35.0)		
No	89(89.0)	11(11.0)		
<b>History of retina surgery</b>			0.7674	0.381
No	89(84)	17(16)		
Yes	13(92.9)	1(7.1)		
<b>History of hypertension</b>			0.0065	0.936
Yes	67(84.8)	12(15.2)		
No	35(85.4)	6(14.6)		
<b>RVO</b>			0.746	0.388
No	92(86)	15(14)		

Variable	Ocular Hypertension		$\chi^2$	P-value
	No	Yes		
	n (%)	n (%)		
Yes	10(76.9)	3(23.1)		
<b>CNV</b>			0.398	0.528
No	95(85.6)	16(14.4)		
Yes	7(77.8)	2(22.2)		
<b>VH</b>			0.4132	0.52
No	78(83.9)	15(16.1)		
Yes	24(88.9)	3(11.1)		
<b>DME</b>			0.0793	0.778
No	49(85.96)	8(14.04)		
Yes	53(84.13)	10(15.87)		

**Table 3.** Distribution of ocular hypertension by participant's characteristics.

Variable	CHR(95%CI)	P-value	AHR(95%CI)	P-value
<b>Sex</b>				
Male	Ref			
Female	1.88(0.74-4.76)	0.183		
<b>Age of the participant</b>				
≤70	Ref		Ref	
>70	1.52(0.50-4.61)	0.463	1.01(0.31-3.15)	0.993
<b>Lens status</b>				
Phakic	Ref			
Pseudophakic	1.95(0.73-5.19)	0.183		
<b>Number of Injection</b>	2.24(1.63-3.09)	<0.001	2.17(1.56-3.16)	<0.001
<b>YAG</b>				
Yes	Ref			
No	0.27(0.10-0.69)	0.001	0.33(0.12-0.88)	0.028
<b>Retina Surgery</b>				
No	Ref			
Yes	0.49(0.07-3.71)	0.493		
<b>Hypertension</b>				
Yes	Ref			
No	0.93(0.34-2.49)	0.881		
<b>RVO</b>				
No	Ref			
Yes	1.87(0.54-6.49)	0.318		
<b>CNV</b>				
No	Ref			
Yes	2.05(0.47-8.92)	0.338		

Variable	CHR(95%CI)	P-value	AHR(95%CI)	P-value
<b>VH</b>				
No	Ref			
Yes	0.66(0.19-2.31)	0.526		
<b>DME</b>				
No	Ref			
Yes	0.96(0.38-2.43)	0.928		

**Table 4.** Factors associated with ocular hypertension.

## Discussion

The incidence of ocular hypertension following Bevacizumab Intravitreal injections among patients treated at KCMC Hospital from 2023 to 2024 was found to be 15%, which is notably higher than the reported average in the literature (4% to 15%<sup>[3]</sup>). Several factors contribute to the higher incidence of ocular hypertension observed at KCMC Hospital following anti-VEGF treatment. Patients likely had more advanced retinal diseases, such as diabetic retinopathy or age-related macular degeneration, which are linked to increased ocular hypertension risk. Injection protocols differed, with KCMC using larger volumes (0.1 ml of 2.5 mg Bevacizumab) and more frequent intervals (every 6 weeks) compared to the smaller doses and treat-and-extend protocols in other settings. Variations in injection techniques and post-injection care, including the use of prophylactic drugs, may also play a role. Additionally, this study employed a stricter definition for ocular hypertension, requiring both an IOP > 21 mmHg and an increase of more than 5 mmHg from baseline, likely capturing more cases than studies using a single criterion.

Comparative studies provide additional context: Belgic et al. comparing Aflibercept and Ranibizumab, reported a much lower incidence of ocular 8.91%, the different can be explained by their different operational definition used (IOP $\geq$ 6mmHg and/or >24mmHg on 2 or more consecutive visits)<sup>[13]</sup>. Aref et al. reported an 8.0% incidence of IOP increases over 60 months, lower than our study's potentially due to different operational definition (IOP>10mmHg)<sup>[14]</sup>. Maruyama-Inoue et al. reported a 7% incidence of

persistent IOP elevation in a Japanese cohort, lower than at KCMC, possibly due different operational definition used (IOP  $\geq$  25mmHg)<sup>[4]</sup>.

Our findings indicate that Bevacizumab injections cause temporary increases in intraocular pressure, which become more frequent and severe with repeated treatments. While IOP levels typically return to normal within an hour, the normalization process slower with number of injection. In contrast, non-injected eyes rarely experience such changes.

The temporary IOP spike five minutes after injection is due to the mechanical response of increased intraocular volume, which may deform the lamina cribrosa and reduce ocular perfusion pressure, disturbing axonal transport. Rapid IOP normalization within 30 minutes suggests effective compensation by outflow mechanisms like the trabecular meshwork and uveoscleral pathways. The increased IOP spikes and delayed normalization after the third injection may result from cumulative effects of repeated injections, including subtle changes in ocular tissue compliance or mild inflammation. Similarly, Dettoraki et al. found that prophylactic treatment with brinzolamide-brimonidine significantly reduced IOP spikes post-injection, with the control group showing higher IOP levels at one, ten, and thirty minutes compared to the case group<sup>[9]</sup>.

Similarly Lemos-Reis et al. found a significant post-injection IOP rise immediately on injected eye only<sup>[15]</sup> Conversely a study by Kato et al. in retinopathy of prematurity reported IOP spike immediately after injection and at five minutes but with normalization within fifteen minutes of injection<sup>[10]</sup>. Our study showed a similar rapid normalization within thirty minutes for most patients, reinforcing the transient nature of post-injection IOP spikes. The slight difference in normalization time might be due to variations study population (premature infant) and injection volume (0.625 mg/0.025 cc).

Despite these cumulative effects, the overall transient nature of the IOP spikes and the effective natural compensation mechanisms underline the safety and reliability of Intravitreal Bevacizumab injections in managing retinal conditions

With every unity increase in the number of injections was significant associated with ocular hypertension. The results of our study align with several previous studies<sup>[4][5][16][17]</sup>. The consistency across these studies may be attributed to the common biological mechanism at play. This correlation can be explained by several underlying biological mechanisms, chronic inflammation and fibrosis in the trabecular meshwork (TM) and Schlemm's canal impair aqueous humor outflow, mechanical obstruction

caused by high-molecular-weight protein aggregates and Repeated injections cause micro trauma, leading to the deposition of cellular debris and protein aggregates that obstruct outflow channels.

The presence of small particles, such as immune complexes, accumulating and occluding the trabecular meshwork, has been suggested as a potential mechanism by Hoang et al.<sup>[16]</sup>. Additionally Liu et al. reported that compounded Bevacizumab held in plastic syringes contained protein aggregates and silicone oil microdroplets, which could potentially block aqueous outflow or induce inflammatory trabeculitis<sup>[18]</sup>.may also result from VEGF inhibition in the trabecular meshwork, reducing aqueous outflow facility, as proposed by Fujimoto et al.<sup>[19]</sup>.

Furthermore, in vitro studies by Kahook and Ammar show high Bevacizumab concentrations may damage TM cells<sup>[20]</sup>.

The influence of YAG laser capsulotomy on IOP elevation is another salient finding in our study, corroborating the results of Sternfeld et al.<sup>[7]</sup>.Our findings indicate YAG laser capsulotomy significantly increases the risk of ocular hypertension, especially in patients receiving anti-VEGF injections. This risk arises from multifactorial mechanisms. The procedure induces transient inflammation, releasing cytokines that disrupt the trabecular meshwork. Disruption of the posterior capsule allows lens particles and inflammatory debris to enter the anterior chamber, physically obstructing the trabecular meshwork and impairing aqueous outflow. Additionally, structural changes in the lens capsule and surrounding tissues alter aqueous humor dynamics, creating inefficient drainage pathways and leading to fluid accumulation. Chronic low-grade inflammation and fibrosis from prolonged healing further exacerbate the risk of sustained IOP elevation in susceptible individuals. Conversely, Hoang et al. reported no significant association between YAG capsulotomy and ocular hypertension. This divergence might be attributable to variations in study populations, differences in follow-up durations, or due to differing intervals since the capsulotomy procedure<sup>[16]</sup>

Limitations of the study include using the Icare tonometer, which isn't the gold standard for IOP measurement, and the possible influence of topical steroid use. To mitigate these, steroids were applied less frequently (twice daily for seven days), and the mean IOP at each visit was calculated by averaging three separate measurements. Conclusion our study at KCMC Hospital found a higher incidence of ocular hypertension following Bevacizumab Intravitreal injections compared to other studies, significant factors associated with ocular hypertension included the frequency of injections and a history of YAG laser capsulotomy. The stringent definition of ocular hypertension applied in our study likely contributed



to the higher incidence. While most patients experienced rapid IOP normalization, cumulative effects from repeated injections led to delayed normalization and increased IOP spikes.

## Statements and Declarations

### *Acknowledgements*

We thank Kevin Rwegoshola for data analysis.

### *Conflicts of Interest*

The authors declare that they have no conflict of interest.

### *Author Contributions*

- *Conceptualization:* John A. Ambakisye.
- *Formal analysis:* John A. Ambakisye, Kevin Rwegoshola.
- *Funding acquisition:* John A. Ambakisye.
- *Investigation:* John A. Ambakisye.
- *Supervision:* John A. Ambakisye, Furahin. G.Mndeme, William Makupa
- *Methodology:* John A. Ambakisye.
- *Project administration:* John A. Ambakisye.
- *Writing – original draft:* John A. Ambakisye.
- *Review & editing:* John A. Ambakisye, Furahin. G.Mndeme, William Makupa

## References

1. <sup>△</sup>Henriques C, da Ana R, Krambeck K, Miguel S, Santini A, Zielińska A, et al. Monoclonal Antibodies for the Treatment of Ocular Diseases. *J Clin Med.* 2024;13(19).
2. <sup>△</sup>Ucguç AY, Aktas Z, Ozgur A, Cubuk MO, Hasanreisoglu M, Ozdek S, et al. Sustained elevation of intraocular pressure after administration of intravitreal anti-vascular endothelial growth factor agents in patients with and without pseudoexfoliation syndrome. *J Glaucoma.* 2020;29(10):981–8.
3. <sup>a, b, c</sup>Hoguet A, Chen PP, Junk AK, Mruthyunjaya P, Nouri-Mahdavi K, Radhakrishnan S, et al. The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the A

- merican Academy of Ophthalmology. *Ophthalmology* [Internet]. 2019;126(4):611–22. Available from: <https://doi.org/10.1016/j.ophtha.2018.11.019>
4. <sup>a, b, c</sup>Maruyama-Inoue M, Inoue T, Mohamed S, Kitajima Y, Ikeda S, Ito A, et al. Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration. *Sci Rep* [Internet]. 2021;11(1):1–5. Available from: <https://doi.org/10.1038/s41598-021-91832-w>
  5. <sup>a, b</sup>Cui QN, Gray IN, Yu Y, VanderBeek BL. Repeated intravitreal injections of anti-vascular endothelial growth factors and risk of intraocular pressure medication use. *Graefe's Arch Clin Exp Ophthalmol*. 2019;257(9):1931–9.
  6. <sup>Δ</sup>Hannappe MA, Baudin F, Mariet AS, Gabrielle PH, Arnould L, Bron AM, et al. Mid-Term Impact of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure. *J Clin Med*. 2022;11(4).
  7. <sup>a, b</sup>Sternfeld A, Ehrlich R, Weinberger D, Dotan A. Effect of different lens status on intraocular pressure elevation in patients treated with anti-vascular endothelial growth factor injections. *Int J Ophthalmol*. 2020;13(1):79–84.
  8. <sup>Δ</sup>Tsui JL, Lau IH, Li SL, Chan NC, Young AL. Predictors of elevated intraocular pressure after intravitreal injection of anti-vascular endothelial growth factor: a prospective observational study. *Hong Kong J Ophthalmol*. 2021;25(1):6–11.
  9. <sup>a, b</sup>Dettoraki M, Rapti E, Fragkos D, Theiopoulos I, Legaki A, Gkounta A, et al. Prophylactic effect of brinzolamide–brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections. *Int Ophthalmol* [Internet]. 2021;41(9):3191–8. Available from: <https://doi.org/10.1007/s10792-021-01885-z>
  10. <sup>a, b</sup>Kato A, Okamoto Y, Okamoto F, Saito M, Miyazono Y, Oshika T. Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity. *Jpn J Ophthalmol* [Internet]. 2019;63(3):262–8. Available from: <https://doi.org/10.1007/s10384-019-00661-y>
  11. <sup>Δ</sup>Kiddee W, Montriwet M. Intraocular pressure changes in non-glaucomatous patients receiving intravitreal anti-vascular endothelial growth factor agents. *PLoS One*. 2015;10(9):7–13.
  12. <sup>Δ</sup>Mansoori T, Agraharam S, Manwani S, Balakrishna N. Intraocular pressure changes after intravitreal bevacizumab or ranibizumab injection: A retrospective study. *J Curr Ophthalmol*. 2021;33(1):6–11.
  13. <sup>Δ</sup>Bilgic A, Kodjikian L, Chhablani J, Sudhalkar A, Trivedi M, Vasavada V, et al. Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab. *J Ophthalmol*. 2020;2020.
  14. <sup>Δ</sup>Aref AA, Scott IU, Vanveldhuisen PC, King J, Ip MS, Blodi BA, et al. Intraocular Pressure-Related Events after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion

on or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial. *JAMA Ophthalmol.* 2021;139(12):1285–91.

15. <sup>△</sup>Lemos-Reis R, Moreira-Gonçalves N, Melo AB, Carneiro ÂM, Falcão-Reis FM. Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. *Clin Ophthalmol [Internet]*. 2014;8:1383–8. Available from: <https://doi.org/10.2147/OPTH.S64721>
16. <sup>△</sup>, <sup>▷</sup>, <sup>Ⓢ</sup>Hoang Q V, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. *Ophthalmology [Internet]*. 2012;119(2):321–6. Available from: <https://doi.org/10.1016/j.ophtha.2011.08.011>
17. <sup>△</sup>Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. *Cutan Ocul Toxicol.* 2016;35(4):310–4.
18. <sup>△</sup>Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-term storage and product mishandling. *Investig Ophthalmol Vis Sci.* 2011;52(2):1023–34.
19. <sup>△</sup>Fujimoto T, Inoue T, Maki K, Inoue-Mochita M, Tanihara H. Vascular endothelial growth factor - A increases the aqueous humor outflow facility. *PLoS One.* 2016;11(9):1–13.
20. <sup>△</sup>Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. *J Glaucoma [Internet]*. 2010 Sep [cited 2024 Nov 25];19(7):437–41. Available from: [https://journals.lww.com/glaucomajournal/fulltext/2010/09000/in\\_vitro\\_effects\\_of\\_antivascular\\_endothelial.3.aspx](https://journals.lww.com/glaucomajournal/fulltext/2010/09000/in_vitro_effects_of_antivascular_endothelial.3.aspx)

## Declarations

**Funding:** No specific funding was received for this work.

**Potential competing interests:** No potential competing interests to declare.